Key Highlights
- Shares closed at A$20.07 on 18 November 2026, unchanged on the day and down approximately 3.93% over one year.
- Revenue rose 13% to A$10,867 million, including organic growth of 5%.
- Underlying EBITDA rose 11% to A$1,933 million for the year to 30 June 2026.
- Total dividends for the year rose 1 cent to A$1.08 per share.
Sonic Healthcare Limited (ASX:SHL) provides pathology and diagnostic imaging services across several countries. Its shares closed at A$20.07 on 18 November 2026, unchanged for the session and down approximately 3.93% over the past year. The company released its FY2026 results on 20 August 2026 for the year ended 30 June 2026.
Latest Update
On 20 August 2026, Sonic reported Revenue of A$10,867 million, up 13%, including organic growth of 5%. Underlying EBITDA rose 11% to A$1,933 million, while statutory EBITDA was A$1,882 million, up 9%. Underlying net profit rose 17% to A$621 million and underlying Earnings Per Share increased 14% to A$1.256.
The company said the LADR Laboratory Group Acquisition was completed and that integration is progressing, with synergy realisation on schedule. It also completed the sale and leaseback of its Brisbane hub laboratory and commenced digital and artificial intelligence transformation initiatives. Total dividends for the year increased by 1 cent to A$1.08 per share.
Company Background and Sector Context
Sonic's operations include pathology, diagnostic imaging and advanced diagnostics across several geographies. The release notes synergy capture from acquisitions in Switzerland as well as growth in advanced diagnostics.
Diagnostic services are funded through government health schemes and private payers, and volumes depend on clinical Demand and reimbursement settings. Mergers and Capital Investment are common features of the sector.
Sonic operates pathology, diagnostic imaging and related laboratory services across Australia, Europe and other regions. Its underlying EBITDA of A$1,933 million includes contributions from acquisitions completed in recent periods, which the release says have provided synergy benefits. The company also reported growth in advanced diagnostics across multiple geographies, and its statutory net profit was A$608 million.
Risks and Uncertainties
Growth has been driven partly by acquisitions, and the company's results depend on the successful integration of LADR and other recent businesses. The release states that synergies are on schedule, but the realisation of those benefits remains subject to execution.
Reimbursement and funding policies in the company's markets can change, and any change could affect revenue and margins. The digital and AI program is at an early stage, and its costs and benefits will emerge over time.
Acquisition-led growth carries integration risk, and FY26 figures include contributions from businesses acquired in recent periods. The release reports organic revenue growth of 5% alongside total revenue growth of 13%, so the split between the two sources is a point for readers to track in later results.
What to Watch Ahead
Investors will watch synergy realisation from the LADR integration, the progress of the digital and AI program, and the company's capital management decisions in the coming reporting periods.
Investors will track whether synergies from the LADR integration are realised on schedule, the progress of the Brisbane sale and leaseback, and the company's capital management program. Dividend policy and any further acquisitions will also be reviewed in future results, along with the effect of digital and AI initiatives on operating costs.
Taken together, the FY26 release sets out revenue growth, higher underlying earnings and a modest increase in the dividend. The share price has moved lower over the past year, and synergy delivery and the progress of the transformation program will be the next measures of performance.






Please wait processing your request...